Paxlovid (Nirmatrelvir/Ritonavir) : A new approach to Covid-19 therapy?
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative regimen is yet available, therefore patients are forced to rely on supportive and nonspecific therapies. Some SARS-CoV-2 proteins, like the 3 C-like protease (3CLpro) or the major protease (Mpro), have been identified as promising targets for antiviral drugs. The Mpro has major a role in protein processing as well as pathogenesis of the virus, and could be a useful therapeutic target. The antiviral drug nirmatrelvir can keep SARS-CoV-2 from replicating through inhibiting Mpro. Nirmatrelvir was combined with another HIV protease inhibitor, ritonavir, to create Paxlovid (Nirmatrelvir/Ritonavir). The metabolizing enzyme cytochrome P450 3 A is inhibited by ritonavir to lengthen the half-life of nirmatrelvir, so rintonavir acts as a pharmacological enhancer. Nirmatrelvir exhibits potent antiviral activity against current coronavirus variants, despite significant alterations in the SARS-CoV-2 viral genome. Nevertheless, there are still several unanswered questions. This review summarizes the current literature on nirmatrelvir and ritonavir efficacy in treating SARS-CoV-2 infection, and also their safety and possible side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 162(2023) vom: 15. Juni, Seite 114367 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemian, Seyed Mohammad Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.05.2023 Date Revised 22.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.114367 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355236931 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355236931 | ||
| 003 | DE-627 | ||
| 005 | 20231226063926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.114367 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355236931 | ||
| 035 | |a (NLM)37018987 | ||
| 035 | |a (PII)S0753-3322(23)00155-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashemian, Seyed Mohammad Reza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Paxlovid (Nirmatrelvir/Ritonavir) |b A new approach to Covid-19 therapy? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2023 | ||
| 500 | |a Date Revised 22.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative regimen is yet available, therefore patients are forced to rely on supportive and nonspecific therapies. Some SARS-CoV-2 proteins, like the 3 C-like protease (3CLpro) or the major protease (Mpro), have been identified as promising targets for antiviral drugs. The Mpro has major a role in protein processing as well as pathogenesis of the virus, and could be a useful therapeutic target. The antiviral drug nirmatrelvir can keep SARS-CoV-2 from replicating through inhibiting Mpro. Nirmatrelvir was combined with another HIV protease inhibitor, ritonavir, to create Paxlovid (Nirmatrelvir/Ritonavir). The metabolizing enzyme cytochrome P450 3 A is inhibited by ritonavir to lengthen the half-life of nirmatrelvir, so rintonavir acts as a pharmacological enhancer. Nirmatrelvir exhibits potent antiviral activity against current coronavirus variants, despite significant alterations in the SARS-CoV-2 viral genome. Nevertheless, there are still several unanswered questions. This review summarizes the current literature on nirmatrelvir and ritonavir efficacy in treating SARS-CoV-2 infection, and also their safety and possible side effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 3 C-like protease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Nirmatrelvir | |
| 650 | 4 | |a Paxlovid | |
| 650 | 4 | |a Ritonavir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a nirmatrelvir and ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Peptide Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 700 | 1 | |a Sheida, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Taghizadieh, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Memar, Mohammad Yousef |e verfasserin |4 aut | |
| 700 | 1 | |a Hamblin, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Bannazadeh Baghi, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Sadri Nahand, Javid |e verfasserin |4 aut | |
| 700 | 1 | |a Asemi, Zatollah |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzaei, Hamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 162(2023) vom: 15. Juni, Seite 114367 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2023 |g day:15 |g month:06 |g pages:114367 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.114367 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2023 |b 15 |c 06 |h 114367 | ||